Journal of Bioequivalence & Bioavailability

Fascin and versican in acute leukemia: Clinical significance and clinicopathologic correlation

7^th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit

August 29-31, 2016 Atlanta, USA

Nabila Mohamed Hosni El Kramani

Delta University for Science and Technology, Egypt

Posters & Accepted Abstracts: J Bioequiv Availab

Abstract:

Background: Fascin and Versican are involved in proliferation, migration and invasion of cancer cells. In spite of this pivotal role of both Fascin and Versican in many types of human malignancies, little is known about their role in acute leukemia. Objective: To measure plasma and leukocytes concentrations of Fascin and Versican in patients with acute leukemia, and to correlate the results with clinical features and treatment outcome. Method: Twenty-four patients with acute myeloid leukemia (AML), sixteen patients with acute lymphoblastic leukemia (ALL) and fifteen control subjects were included in the current study. Fascin and Versican were measured in plasma and leukocytes of all subjects by enzyme-linked immunosorbent assay kits provided by MyBioSource Inc., (San Diego, CA, USA). Results: Plasma Fascin significantly increased in AML, but not ALL cases. Plasma and leukocytes Versican significantly increased in AML compared to both control and ALL cases. Plasma Versican correlated with poor response to induction chemotherapy in AML cases. Conclusion: All together, Versican may be used as a diagnostic biomarker for AML. The plasma level of Versican could be a novel predictive marker of the response to induction chemotherapy in AML. In addition, plasma Fascin is a potential biomarker for AML.

Biography :

Email: Nabila_ElKramani@hotmail.com